Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO� telotristat ethyl plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer BTC

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03790111

Study #:
STUDY00144232

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03790111

View Complete Trial Details & Eligibility at ClinicalTrials.gov